Candesant Biomedical Introduces New SweatTech Initiative at ASDS

Candesant Biomedical is introducing a new initiative – SweatTech™  – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) patch is single-use, disposable, and unlike anything currently on the market. It is designed to be fast, effective, and affordable with a favorable safety profile.

The SweatTech initiative, which will be featured at an exhibit during ASDS, aims to raise awareness of the significant impact of excessive sweating, educate on how treatments have evolved over the decades, and demonstrate the ongoing need for more modern treatments.

The company says clinical studies show that Candesant’s investigational TAT patch significantly reduces sweat. The TAT patch:

• Uses alkali metal that creates thermal energy when it interacts with underarm sweat, microtargeting sweat glands and temporarily inactivating them to reduce sweating
• Is applied by a healthcare professional for up to three minutes per underarm
• Is currently undergoing review by the FDA for use in reducing underarm sweat 

In a pivotal study, the TAT patch demonstrated significant reductions in sweat measured by both quality of life and quantitative measurements. Specifically, the TAT patch reduced underarm sweat and improved multiple quality of life measures including increased confidence, reduced embarrassment, reduced frustration, and less need for multiple showers and shirt changes. Additionally, the TAT patch showed a favorable safety profile, with no serious adverse events. In fact, 75% of patients had no adverse events.